NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Free XBIO Stock Alerts $3.90 -0.15 (-3.71%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$3.81▼$4.0050-Day Range$3.77▼$4.7252-Week Range$2.55▼$5.97Volume3,379 shsAverage Volume5,566 shsMarket Capitalization$6.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Xenetic Biosciences alerts: Email Address Xenetic Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-1.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.43) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.15 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Xenetic Biosciences.Read more about Xenetic Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 125.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XBIO. Previous Next 0.6 News and Social Media Coverage News SentimentXenetic Biosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xenetic Biosciences this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by InstitutionsOnly 15.12% of the stock of Xenetic Biosciences is held by institutions.Read more about Xenetic Biosciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xenetic Biosciences are expected to grow in the coming year, from ($3.43) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xenetic Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBiggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."Get the details before it's taken offline. About Xenetic Biosciences Stock (NASDAQ:XBIO)Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More XBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIO Stock News HeadlinesApril 10, 2024 | investing.comXenetic Biosciences Inc (XBIO)March 24, 2024 | finance.yahoo.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”March 22, 2024 | baystreet.caXenetic Dips on Full-Year ResultsMarch 22, 2024 | msn.comXenetic Biosciences reports FY resultsJanuary 18, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipJanuary 4, 2024 | morningstar.comXenetic Biosciences Inc XBIODecember 11, 2023 | benzinga.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastMay 10, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”November 30, 2023 | finance.yahoo.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 10, 2023 | benzinga.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | washingtonpost.comMediciNova: Q3 Earnings SnapshotOctober 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceJuly 13, 2023 | msn.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?May 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 3, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationApril 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)April 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformMarch 16, 2023 | finanznachrichten.deJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesFebruary 23, 2023 | seekingalpha.comXBIO Xenetic Biosciences, Inc.February 21, 2023 | reuters.comXBIO.PH - | Stock Price & Latest News | ReutersJanuary 17, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyDecember 15, 2022 | finance.yahoo.comWhy We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllSee More Headlines Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/10/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIO CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,140,000.00 Net Margins-162.84% Pretax Margin-162.79% Return on Equity-36.43% Return on Assets-33.74% Debt Debt-to-Equity RatioN/A Current Ratio11.84 Quick Ratio11.84 Sales & Book Value Annual Sales$2.54 million Price / Sales2.36 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.61Miscellaneous Outstanding Shares1,541,000Free Float1,402,000Market Cap$6.00 million OptionableNot Optionable Beta2.56 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jeffrey F. Eisenberg (Age 53)CEO & Director Mr. James F. Parslow (Age 54)CFO, COO & Corp. Sec. Dr. Curtis A. Lockshin (Age 59)Chief Scientific Officer Key CompetitorsKintara TherapeuticsNASDAQ:KTRAOragenicsNYSE:OGENHoth TherapeuticsNASDAQ:HOTHAyala PharmaceuticalsNASDAQ:ADXSAdial PharmaceuticalsNASDAQ:ADILView All Competitors XBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Xenetic Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares. View XBIO analyst ratings or view top-rated stocks. How have XBIO shares performed in 2024? Xenetic Biosciences' stock was trading at $3.45 at the beginning of 2024. Since then, XBIO shares have increased by 12.9% and is now trading at $3.8955. View the best growth stocks for 2024 here. When is Xenetic Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our XBIO earnings forecast. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.10. The firm earned $0.67 million during the quarter, compared to analysts' expectations of $0.68 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 36.43% and a negative net margin of 162.84%. When did Xenetic Biosciences' stock split? Xenetic Biosciences shares reverse split on the morning of Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIO) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
